Close Menu
    Facebook X (Twitter) Instagram
    SciTechDaily
    • Biology
    • Chemistry
    • Earth
    • Health
    • Physics
    • Science
    • Space
    • Technology
    Facebook X (Twitter) Pinterest YouTube RSS
    SciTechDaily
    Home»Health»New Once-Daily Pill Slashes Bad Cholesterol by Nearly 65% in Clinical Trial
    Health

    New Once-Daily Pill Slashes Bad Cholesterol by Nearly 65% in Clinical Trial

    By Binghamton UniversityNovember 21, 2026No Comments3 Mins Read
    Facebook Twitter Pinterest Telegram LinkedIn WhatsApp Email Reddit
    Share
    Facebook Twitter LinkedIn Pinterest Telegram Email Reddit
    Doctor With Stethoscope Holding White Pill Medicine
    A newly approved oral medication dramatically lowered LDL cholesterol in clinical trials, even among patients already taking statins. Credit: Shutterstock

    A pill taken before breakfast cut “bad” cholesterol by nearly two-thirds in a trial of people already taking statins.

    High cholesterol can silently damage blood vessels for decades, increasing the risk of heart attacks and strokes without causing noticeable symptoms. Much of that danger comes from excess LDL (“bad”) cholesterol, which contributes to fatty plaque buildup inside artery walls. Although statins help millions of people control their cholesterol, some patients need additional treatment to bring their levels down.

    A newly approved once-daily pill could provide another option. Lipfendra (enlicitide) reduced LDL cholesterol by nearly 65% in a clinical trial involving adults already taking statins. Approved by the FDA on July 16, 2026, it is the first oral medication in a powerful class of cholesterol treatments previously available only through injections.

    How the New Cholesterol Pill Works

    Enlicitide targets PCSK9, a protein that influences how efficiently the liver removes LDL cholesterol from the bloodstream. Normally, PCSK9 promotes the destruction of LDL receptors on liver cells. When these receptors are lost, the liver becomes less effective at clearing circulating cholesterol.

    By blocking PCSK9, enlicitide allows more LDL receptors to remain active, helping the liver remove additional cholesterol from the blood. Unlike earlier PCSK9 inhibitors that require injections, enlicitide uses a specialized macrocyclic peptide formulation with absorption-enhancing ingredients, allowing the medication to be taken orally.

    How Much Can It Lower Cholesterol?

    A review published in Annals of Pharmacotherapy found that enlicitide reduced LDL cholesterol by 57.1% to 64.6% after 24 weeks across clinical trials. These reductions were comparable to those achieved with injectable PCSK9 inhibitors.

    In a direct comparison involving patients already taking statins, LDL cholesterol fell by approximately 65% with enlicitide. By comparison, reductions were about 28% with ezetimibe and 6% with bempedoic acid, two other oral medications used to manage high cholesterol.

    What Clinical Trials Found About Safety

    The review examined research identified through PubMed, Embase, Web of Science, and Cochrane through July 17, 2026. Participants included adults with elevated cholesterol and those with heterozygous familial hypercholesterolemia, an inherited condition that causes unusually high LDL cholesterol levels from birth and increases the risk of premature cardiovascular disease.

    In the largest trial, adverse effects occurred at similar rates among participants receiving enlicitide and those taking a placebo. However, a separate study involving people with inherited high cholesterol reported more diarrhea and dizziness among those receiving the medication. Longer-term monitoring will help establish its safety with continued use.

    A Daily Tablet With Specific Dosing Requirements

    Enlicitide must be taken in the morning on an empty stomach. Patients may drink water, black coffee, or plain tea with the medication but must wait at least 30 minutes before consuming food or other beverages. A 30-day supply carries a list price of $315, although actual costs depend on insurance coverage.

    While clinical trials have established that enlicitide substantially reduces LDL cholesterol, researchers have not yet determined whether it also prevents heart attacks and strokes. An ongoing cardiovascular outcomes trial is investigating whether its cholesterol-lowering effects translate into fewer serious cardiovascular events.

    Reference: “Enlicitide: The First Oral PCSK9i for Lowering Low-Density Lipoprotein Cholesterol” by Rachel C. Lucas, Mia E. Lussier, Azadeh Nasuhidehnavi and Taylor M. Clark, 14 October 2026, Annals of Pharmacotherapy.
    DOI: 10.1177/10600280261494015

    Never miss a breakthrough: Join the SciTechDaily newsletter.
    Follow us on Google and Google News.

    Cardiology Cholesterol Drugs Pharmaceuticals Public Health SUNY
    Share. Facebook Twitter Pinterest LinkedIn Email Reddit

    Related Articles

    Major Study Debunks Common Myths About Statin Side Effects

    Scientists Uncover New Concerns About Billion-Dollar Heart Drug

    Trans Fats Are Worse Than You Think: A New Threat Beyond Cholesterol

    Clinical Trial Confirms: Nasal Spray Safely Treats Recurrent Abnormal Heart Rhythms

    Coffee’s Link to Raised Cholesterol Depends on Drinker’s Sex Plus Brewing Method

    Cholesterol-Lowering Statins Linked to Reduced Risk of Death From COVID-19 in Major Study

    Researchers Call for Therapeutics To Treat Cholesterol Cousins Called Ceramides – Linked to Many Health Problems

    New Analysis of Pre-COVID-19 Reports Reveals Heart-Related Side Effects of Hydroxychloroquine and Chloroquine

    Research Shows Cardiac Safety of Hydroxychloroquine in COVID-19 Patients – Not Associated With Dangerous Heart Rhythms

    Leave A Reply Cancel Reply

    • Facebook
    • Twitter
    • Pinterest
    • YouTube

    Don't Miss a Discovery

    Subscribe for the Latest in Science & Tech!

    Trending News

    Stanford Scientists Discover 3 Hidden Brain Types in Children With ADHD and Anxiety

    What Is a Thought Made Of? Scientists Reveal Why Human Consciousness May Be Beyond the Reach of AI

    Scientists Discover Mysterious Toxic Chemicals Floating in the Air Above America

    Astronomers Discover a Chilling Preview of Our Solar System’s Future

    Scientists Discover Alarming Signs of Extinction Risk Deep Beneath the Ocean

    A Common Gut Antibody May Be the Key to Preventing Colon Cancer Before It Starts

    Scientists Discover a Disturbing Link Between Cannabis Use and Earlier Psychosis

    Scientists Discover Two Monster Black Holes at the Dawn of Time That Shouldn’t Exist

    Follow SciTechDaily
    • Facebook
    • Twitter
    • YouTube
    • Pinterest
    • Newsletter
    • RSS
    SciTech News
    • Biology News
    • Chemistry News
    • Earth News
    • Health News
    • Physics News
    • Science News
    • Space News
    • Technology News
    Recent Posts
    • New Once-Daily Pill Slashes Bad Cholesterol by Nearly 65% in Clinical Trial
    • An Overlooked Property of Light Could Open the Door to a New Era of Optical Computing
    • NASA Smashed Into an Asteroid. Now ESA’s Hera Spacecraft Is About to Reveal the Damage
    • Does the Sun Have a Secret Companion? A Controversial Theory Could Explain Earth’s Mass Extinctions
    • Scientists Develop New Nanomaterial That Could Help the Body Regrow Missing Bone
    Copyright © 1998 - 2026 SciTechDaily. All Rights Reserved.
    • Science News
    • About
    • Contact
    • Editorial Board
    • Privacy Policy
    • Terms of Use

    Type above and press Enter to search. Press Esc to cancel.